flowchart TD
A[HIDA Scan Performed] --> B{Was a medication administered\nduring the imaging protocol?}
B -->|Yes| C{Is the medication documented\nin the report?}
B -->|No| D[Bill 78226\nStandard hepatobiliary imaging]
C -->|Yes| E{Does the report include:\n- Drug name and route\n- Timing in imaging sequence\n- Quantitative result or diagnostic effect?}
C -->|No| F[Query physician for addendum\nor bill 78226]
E -->|Yes| G[Bill 78227\nWith pharmacologic intervention]
E -->|No| F
B -->|Fatty meal only| D
style G fill:#2d8659,color:#fff
style D fill:#2d8659,color:#fff
style F fill:#d4a017,color:#fff
Hepatobiliary iminodiacetic acid (HIDA) scans -- also called hepatobiliary scintigraphy -- are nuclear medicine studies that trace the production and flow of bile from hepatic uptake into the biliary tree, gallbladder (when present), and small bowel. Although the exam is commonly referred to as a single "HIDA," billing in CPT is intentionally split into two distinct codes that reflect whether a medication is administered during imaging and whether additional quantitative work is performed.
Mutual exclusivity: 78227 is not an add-on to 78226. It represents the full hepatobiliary study with pharmacologic intervention. A single encounter should be billed as either 78226 or 78227 -- never both -- for the same study session. Coding analyses and payer policies treat them as alternative representations of one HIDA exam depending on protocol.
The clinical question frequently predicts the correct CPT code -- provided the protocol aligns with the question. Common variants include:
A recurring compliance issue arises when facilities substitute a fatty meal for medication-based stimulation. Policy language and many utilization management frameworks treat dietary stimulation as non-pharmacologic, which generally leads back to 78226. This is not a minor detail: it is one of the most common reasons claims are downcoded or denied, because the billed CPT must match what was actually administered and documented.
Medicare coverage for HIDA scans is typically governed by the general "reasonable and necessary" standard rather than a single national coverage determination, so the operational reality is shaped by local contractor articles, payer edits, and prior authorization rules. Commercial payers are often more explicit, publishing medical policies that set prerequisites and narrow indications. The most consistent theme across modern coverage documents is stepwise evaluation: HIDA is often supported after ultrasound is nondiagnostic or inconclusive, particularly for suspected gallbladder disease.
For commercial plans, prior authorization is common for nuclear medicine, and documentation requirements are frequently operationalized in pre-certification questionnaires. Referral documentation tools can ask about prior imaging, duration and location of pain, and suspected diagnosis before approving HIDA.
In addition, payer policy updates can change practical coverage expectations over time, particularly within Medicare Advantage plan ecosystems. Provider-facing policy update notices show that coverage and protocol rules can shift with effective dates, which makes it important to verify the current version of medical policy during preauthorization and claim preparation.
For HIDA coding, documentation is not merely best practice; it is often the difference between correct reimbursement and downcoding. A "HIDA with CCK" that lacks explicit medication documentation is, from a payer's point of view, indistinguishable from a standard HIDA. Coding guidance and reimbursement analyses emphasize that the report should clearly reflect whether pharmacologic intervention was performed.
If billing 78227, the report should explicitly include the medication and its role in the protocol. The medication is part of the imaging technique, and the results (often ejection fraction) represent an intentional diagnostic output.
Documentation example: CCK-HIDA (supports 78227)
Technique: "Tc-99m IDA agent administered IV. Dynamic hepatobiliary images obtained for 60 minutes. Sincalide (Kinevac) administered during imaging per protocol to evaluate gallbladder function. Post-stimulation images obtained and gallbladder ejection fraction calculated."
Result: "Gallbladder ejection fraction 22% (low)."
Impression: "Low ejection fraction consistent with functional gallbladder disorder in appropriate clinical context."
When coders see a report that lists an ejection fraction but never mentions medication, the compliant response is generally to code 78226 or to query the interpreting physician for an addendum that documents the medication if it was actually given. The central principle remains: if it is not documented, it should not be billed.
HIDA codes are PC/TC split-eligible, which means billing depends on who owns the technical resources and who performs interpretation.
Use -26 when billing the physician interpretation only, most often when the scan occurs in a hospital or facility that bills the technical component. This is standard in hospital outpatient and inpatient settings.
Use -TC when billing the technical side only (camera, radiopharmaceutical handling, technologist labor, supplies), commonly for freestanding imaging centers or IDTFs when the interpreting physician bills separately with -26. Hospitals typically bill without "TC" on UB-04 claims under OPPS, but non-hospital technical claims often require the explicit TC modifier.
Because 78227 is not an add-on code, modifier -59 should not be used to "separate" 78226 from 78227. A single study should be coded as one or the other. Attempts to override mutual exclusivity edits by appending -59 are commonly denied and can create audit risk.
If an exceptionally unusual clinical situation results in a legitimately repeated HIDA study on the same date of service (separate session), the more appropriate repeat modifier is typically -76 rather than -59, with clear documentation of why a repeat study was needed.
The CPT code must be supported by an ICD-10-CM diagnosis that is consistent with the indication and with payer coverage logic. From a medical necessity perspective, many payers accept symptom codes such as right upper quadrant pain when the workup is ongoing, but vague abdominal pain codes are more vulnerable to denial. Clinical guideline pathways for nuclear medicine emphasize alignment between the suspected condition and the imaging choice, particularly when ultrasound is nondiagnostic and biliary disease remains suspected.
| ICD-10 Category | Examples | Typical HIDA Use |
|---|---|---|
| Symptoms (focused) | R10.11 (RUQ pain), R10.13 (epigastric pain) | Supports diagnostic evaluation when ultrasound is nondiagnostic and suspicion remains high. |
| Cholecystitis / gallbladder disorders | K81.0 (acute cholecystitis), K81.1 (chronic), K82.8 (other gallbladder disease) | Acute cholecystitis confirmation; functional disorders when paired with a medication protocol (78227). |
| Biliary obstruction / complications | K83.x series (biliary tract disease) | Transit delay patterns; postoperative or obstructive scenarios depending on clinical picture. |
| Post-procedural states | Post-cholecystectomy symptom/complication codes when applicable | Leak or postoperative biliary complication evaluation (often 78226 unless medication protocol used). |
In practice, claims are stronger when the diagnosis is specific (cholecystitis, bile leak, suspected obstruction) or when symptom codes are clearly linked to a biliary differential with documented nondiagnostic ultrasound. If a plan requires prior authorization, the ICD-10 list used during authorization should match the claim.
Billing arrangement depends on site of service and ownership of the technical resources. The key operational rule is: only one party bills each component, and the professional and technical claims must be consistent in code selection (78226 vs 78227).
Consistency checkpoint: If the radiology report documents a medication protocol (CCK or morphine) and an ejection fraction, both the technical biller and the interpreting physician should be aligned on 78227. Mismatches can create denial risk and complicate appeals.
Reimbursement is driven by RVUs and the annual conversion factor. In broad terms, 78227 reimburses higher than 78226 because of additional clinical labor, extended imaging time, and medication handling.
For day-to-day operations, many practices monitor payments using two complementary resources: (1) code-specific RVU and fee schedule pages (useful for relative valuation and splits), and (2) a consolidated physician fee schedule publication for the year (useful for macro changes and cross-checks on conversion factor effects).
Most preventable HIDA denials fall into three buckets: (1) protocol/documentation mismatch (especially 78227 without drug documentation), (2) incorrect component billing/modifiers, and (3) medical necessity (diagnosis/policy criteria not met).
This is the highest-yield compliance risk. If the report does not state the medication administration (and timing), payers often downcode to 78226 or deny. Because policy language expects a pharmacologic intervention to justify the "with drug" code, documentation is the proof element.
Because 78227 already represents the complete hepatobiliary imaging service with intervention, billing both codes is treated as incorrect unbundling. Claims edits often deny one line, and repeated occurrences can trigger audit attention. The split is not base + add-on; it is one code selection per encounter.
Professional-only claims without -26 in a hospital setting may deny or pay incorrectly. Conversely, billing global when another entity already billed the technical portion risks duplicate billing allegations.
HIDA is commonly justified when ultrasound is nondiagnostic and biliary disease remains suspected, but claims can fail when the diagnosis is too vague or when documentation does not show that standard first-line evaluation occurred. Payers may require explicit symptom localization, prior imaging results, and indication-specific criteria.
Get instant expert-level medical coding assistance.